WO2006097024A1 - Procede de preparation et utilisation de pansement medical antiseptique - Google Patents
Procede de preparation et utilisation de pansement medical antiseptique Download PDFInfo
- Publication number
- WO2006097024A1 WO2006097024A1 PCT/CN2005/002290 CN2005002290W WO2006097024A1 WO 2006097024 A1 WO2006097024 A1 WO 2006097024A1 CN 2005002290 W CN2005002290 W CN 2005002290W WO 2006097024 A1 WO2006097024 A1 WO 2006097024A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- medical dressing
- dressing
- reaction
- chitosan
- hours
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 26
- 230000002421 anti-septic effect Effects 0.000 title abstract 3
- 229920001661 Chitosan Polymers 0.000 claims abstract description 100
- 239000000835 fiber Substances 0.000 claims abstract description 70
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims abstract description 58
- 238000006243 chemical reaction Methods 0.000 claims abstract description 53
- 206010052428 Wound Diseases 0.000 claims abstract description 48
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 48
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 238000004806 packaging method and process Methods 0.000 claims abstract description 12
- 230000001684 chronic effect Effects 0.000 claims abstract description 9
- 239000002253 acid Substances 0.000 claims abstract description 8
- 238000005520 cutting process Methods 0.000 claims abstract description 8
- 239000000243 solution Substances 0.000 claims description 67
- 239000004745 nonwoven fabric Substances 0.000 claims description 54
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 53
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 claims description 32
- 230000000844 anti-bacterial effect Effects 0.000 claims description 31
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 30
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 claims description 21
- 229940106681 chloroacetic acid Drugs 0.000 claims description 21
- 229910052709 silver Inorganic materials 0.000 claims description 21
- 239000004332 silver Substances 0.000 claims description 21
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 20
- 230000035484 reaction time Effects 0.000 claims description 19
- -1 silver ions Chemical class 0.000 claims description 18
- 238000004132 cross linking Methods 0.000 claims description 17
- 238000004519 manufacturing process Methods 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 16
- 229910001961 silver nitrate Inorganic materials 0.000 claims description 16
- 238000011282 treatment Methods 0.000 claims description 16
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 10
- 238000010559 graft polymerization reaction Methods 0.000 claims description 10
- 230000004048 modification Effects 0.000 claims description 10
- 238000012986 modification Methods 0.000 claims description 10
- 208000002847 Surgical Wound Diseases 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 9
- 238000009832 plasma treatment Methods 0.000 claims description 9
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 8
- 239000002245 particle Substances 0.000 claims description 8
- 229910001415 sodium ion Inorganic materials 0.000 claims description 8
- 230000000249 desinfective effect Effects 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 5
- 230000008878 coupling Effects 0.000 claims description 5
- 238000010168 coupling process Methods 0.000 claims description 5
- 238000005859 coupling reaction Methods 0.000 claims description 5
- 238000009987 spinning Methods 0.000 claims description 5
- 238000001291 vacuum drying Methods 0.000 claims description 5
- 238000007605 air drying Methods 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 239000008055 phosphate buffer solution Substances 0.000 claims description 4
- 230000000845 anti-microbial effect Effects 0.000 claims description 3
- 230000002439 hemostatic effect Effects 0.000 claims description 3
- 239000004599 antimicrobial Substances 0.000 claims description 2
- 239000002131 composite material Substances 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 235000009161 Espostoa lanata Nutrition 0.000 claims 1
- 240000001624 Espostoa lanata Species 0.000 claims 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims 1
- 102220527235 Sphingosine 1-phosphate receptor 1_T80Y_mutation Human genes 0.000 claims 1
- 239000003431 cross linking reagent Substances 0.000 claims 1
- 229910017604 nitric acid Inorganic materials 0.000 claims 1
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 9
- 230000029663 wound healing Effects 0.000 abstract description 6
- 210000001124 body fluid Anatomy 0.000 abstract description 4
- 239000010839 body fluid Substances 0.000 abstract description 4
- 238000001356 surgical procedure Methods 0.000 abstract description 4
- 241000894006 Bacteria Species 0.000 abstract description 3
- 206010061218 Inflammation Diseases 0.000 abstract description 2
- 230000000694 effects Effects 0.000 abstract description 2
- 239000004744 fabric Substances 0.000 abstract description 2
- 230000004054 inflammatory process Effects 0.000 abstract description 2
- 230000036407 pain Effects 0.000 abstract description 2
- 239000003513 alkali Substances 0.000 abstract 2
- 241000521257 Hydrops Species 0.000 abstract 1
- 206010030113 Oedema Diseases 0.000 abstract 1
- 206010053615 Thermal burn Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000001954 sterilising effect Effects 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 23
- 239000000523 sample Substances 0.000 description 21
- 239000007788 liquid Substances 0.000 description 14
- 238000010521 absorption reaction Methods 0.000 description 8
- 239000013068 control sample Substances 0.000 description 7
- 230000035876 healing Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 229920000742 Cotton Polymers 0.000 description 5
- 238000006116 polymerization reaction Methods 0.000 description 5
- 239000004971 Cross linker Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000023597 hemostasis Effects 0.000 description 4
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 229920002101 Chitin Polymers 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 230000003628 erosive effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 238000010382 chemical cross-linking Methods 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000011261 inert gas Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000009940 knitting Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241001674044 Blattodea Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 238000009920 food preservation Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 238000004154 testing of material Methods 0.000 description 1
- 238000009489 vacuum treatment Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/0203—Adhesive bandages or dressings with fluid retention members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
- D01F9/00—Artificial filaments or the like of other substances; Manufacture thereof; Apparatus specially adapted for the manufacture of carbon filaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
- A61L2300/104—Silver, e.g. silver sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
Definitions
- the present invention relates to a method of making a medical dressing, and more particularly to a method of making an antimicrobial medical dressing; and further to the use of the antimicrobial medical dressing.
- a dressing In the treatment of chronic wounds, a dressing is required to absorb a large amount of exudate from the wound and at the same time speed up the healing of the wound.
- the absorption capacity of alginate dressings currently in large use on the market is not ideal for wounds with a large amount of exudation.
- W094/16746 discloses a surgical dressing containing carboxymethylcellulose which is capable of absorbing 15 times its own weight of saline and can be used for surgery and for handling chronic wounds.
- W099/02093 also discloses a wound dressing made of carboxymethylcellulose and a method of making the same.
- these two inventions can only achieve the purpose of accelerating wound healing by providing a moist environment. Therefore, innovating a medical biological antibacterial healing dressing that can both anti-inflammatory and hemostasis without sticking to the wound and at the same time being absorbed by the human body is undoubtedly a practical work for the treatment of surgery and burns and the reduction of patient suffering.
- Polyacetylglucosamine commonly known as chitosan
- chitosan is a polysaccharide widely distributed in nature. It is the main component of various fungal cell walls and shells of shrimp, crab and insects.
- the unique properties of lysozyme in the body that can be absorbed by the body tissues.
- the material is non-toxic, tasteless, has good compatibility with the body tissues, has no immune antigen reaction, and has antibacterial, anti-inflammatory, hemostasis, analgesic and healing functions.
- Carboxymethyl chitosan is a class of chitin derivatives produced by the reaction of chitosan with a carboxymethyl group.
- carboxymethyl chitosan has a very wide range of uses and is of great significance in the development of food preservation, cosmetics and pharmaceutical industries. Chen Lingyun and so on
- US 20050058694 refers to a partial carboxymethyl chitosan surgical dressing
- the carboxymethyl process is a one-step method directly immersing chitosan fibers in a water/alcohol solution mixed with chloroacetic acid and sodium hydroxide.
- the dressing is a translucent gel-like substance when it meets water, and the fiber structure is visible.
- the carboxymethylated fiber is made into a non-woven fabric by a non-woven process, since the carboxymethylated fiber is easy to absorb water, it will open to the subsequent non-woven fabric, and it will be difficult to form a net, and it will be non-woven. After the machine is machined, the oil on the surface of the carboxymethylated fiber will make the non-woven fabric hydrophobic, which affects the liquid absorption performance of the dressing. Summary of the invention
- One of the technical problems to be solved by the present invention is to provide a method for manufacturing an antibacterial medical dressing for use in surgical wounds, burns, burns and other chronic wounds, covering the wound surface to prevent moisture loss in the body fluid, and providing an active wound healing.
- Another technical problem to be solved by the present invention is that in the prior art, when the carboxymethylated fiber is formed into a nonwoven fabric by a nonwoven process, it is disadvantageous in that it causes hydrophobicity, which affects the liquid absorbing property of the dressing. ,
- the third technical problem to be solved by the present invention is that, in the prior art, when the carboxymethylated fiber is made into a non-woven fabric by a non-woven process, since the carboxymethylated fiber is easily absorbed, the non-woven fabric is given to the back. The opening during processing brings difficulties to the network.
- the present invention utilizes the following two-step method to prepare a carboxymethyl chitosan dressing: 'The chitosan fiber is immersed in a concentration of 40 to 50% NaOH solution, and the bath ratio is 1:20 to 60, and the reaction is carried out at room temperature. 0. 5 ⁇ 6 hours, the alkalized chitosan fiber is formed, and the alkalized product is washed with anhydrous alcohol;
- the product is reacted with chloroacetic acid in isopropanol, the concentration of chloroacetic acid is 20 to 40%, the reaction temperature is 35 to 75 ° C, the reaction time is 1 to 8 hours, the reaction is completed, the excess solution is removed, and the solution is washed with absolute ethanol. , air drying is carboxymethyl chitosan fiber.
- the air-dried carboxymethyl chitosan fiber is opened, netted, and needled to make a non-woven fabric of 30 ⁇ 200g/m 2 , which can be made into carboxymethyl chitosan after cutting, packaging and disinfection. dressing.
- the chitosan fiber is added before the air is dried, and the ratio of the chitosan fiber to the carboxymethyl chitosan fiber is 1:9 to 9:1.
- the strength of the medical dressing can be further improved.
- the medical dressing prepared by the present invention may also be added with additives by various means to change or improve its therapeutic efficacy.
- additives for example, in the preparation of the above chitosan fiber, nano silver is added to improve the bactericidal effect of the dressing.
- the preparation method is as follows:
- the nano-sized silver particles are added in a ratio of 0.1% to 1% by mass in the spinning solution;
- the two-step preparation of the carboxymethyl chitosan dressing can also be:
- the chitosan fiber is cut, opened, netted, and needled to form a non-woven fabric of 30 to 200 g/m 2 ;
- the alkalized chitosan non-woven fabric is formed by immersing the nonwoven fabric in a concentration of 40 to 50% NaOH, a bath ratio of 1:20 to 60, and a reaction at room temperature of 0.5 to 6 hours. Washing with water alcohol;
- the product is reacted with chloroacetic acid in isopropanol, the concentration of chloroacetic acid is 20 to 40%, the reaction temperature is 35 to 75 ° C, the reaction time is 1 to 8 hours, the reaction is completed, the excess solution is removed, and the solution is washed with absolute ethanol. Air drying
- the above dressing swells in contact with water to form an elastic gel body, which can absorb about 30 times its own weight, which is much higher than other medical dressings.
- the gamma value of the carboxymethyl group is 0. 4 to 0. 8 ⁇
- the carboxy group of the carboxymethyl group is 0. 4 to 0.
- the medical dressing prepared by the invention can also change or improve the therapeutic effect by the following means, that is, introducing silver ions in the preparation of the carboxymethyl chitosan fiber or the carboxymethyl chitosan nonwoven fabric to improve the bactericidal effect of the dressing,
- the preparation method is as follows:
- the medical dressing prepared by the present invention can also be improved in hydrophilicity by plasma treatment, and its water retention property can be improved by crosslinking treatment.
- the mechanism of plasma treatment to improve the hydrophilicity of the medical dressing is to use plasma treatment to open the chemical bond on the surface of the medical dressing to facilitate the grafting of hydrophilic groups in the case of an inert gas or a hydrophilic substance as a carrier.
- plasma-initiated polymerization is a process in which the plasma is irradiated as a source of energy for a short period of time (several seconds to several minutes) and then placed at an appropriate temperature to initiate the reaction from the gas phase, and the chain growth and chain termination reactions are in the liquid phase or Made in the solid phase.
- the low temperature plasma initiated reaction can effectively improve the characteristics of biomedical materials.
- the characteristics are as follows: (1) The depth of action on the surface of the material is only tens of nanometers, which does not affect the properties of the matrix material; (2) It can handle various shapes. Surface; (3) has a strong bactericidal effect, is an ideal surface treatment technology for biomedical materials.
- the prepared medical dressing is subjected to atmospheric pressure plasma treatment, and under normal pressure, the plasma discharge is performed, and the discharge power is 20 W to 100 W, and the discharge time is 10 seconds to 30 minutes, and then placed in a certain hydrophilic state. Soak in a solution for 5 seconds to 60 minutes.
- the prepared medical dressing is subjected to low temperature plasma treatment, and the prepared non-woven fabric dressing is placed side by side in a plasma reaction device connected with a capacitive coupling;
- the dressing is subjected to hydrophilic grafting or polymerization, and the working condition is that the modified gas is passed into the reactor under vacuum, and the modified pressure is 20 to 80 Pa, and the modification time is 1 to 30 minutes;
- the graft polymerization is carried out, the background vacuum is 2 to 8 Pa, the glow discharge, the graft polymerization pressure is 10 to 60 Pa, the time is 2 to 60 minutes, and the discharge power is 30 to 80 W.
- the dressing is swollen with water to form an elastic gel, which can absorb more than 30 times its own weight of water, which is higher than the untreated medical dressing.
- the cross-linking treatment of the antibacterial medical dressing is to overcome the defect that the gel formed by the uncrosslinked medical dressing after the liquid is dissolved with a small amount of time, and the cross-linking treatment methods are as follows:
- Thermal cross-linking Put a certain size of medical dressing into a vacuum oven, vacuum, preheat for 1 ⁇ 5 hours at 50 ⁇ 80 °C; raise the temperature of the vacuum drying oven to 80 ⁇ 140 °C. Heat cross-linking treatment for 2 hours to 4 days. The material was taken out after lowering the temperature in the vacuum oven to room temperature while maintaining the vacuum.
- Chemical cross-linking chemically cross-link the prepared medical dressing, immerse a certain size of medical dressing into glutaraldehyde solution, soak for 5 ⁇ 60 minutes at room temperature; adjust the solution to acid with acid, and treat at room temperature 2 ⁇ 48 Hours, the medical dressing was repeatedly rinsed with a phosphate buffer until the uncrosslinked crosslinker was removed.
- UV crosslinking A certain size of medical dressing is placed under a UV lamp with a wavelength of 235 to 300 nm; the time for ultraviolet irradiation of the medical dressing is 5 minutes to 60 minutes, respectively.
- the application of the above plasma and cross-linking treatment method can greatly improve the practicability of the medical dressing, not only further improve the hydrophilicity of the dressing, but also overcome the change of the gel formed by the untreated dressing with water over time. Disadvantages of dissolution. It is used to stop bleeding in various surgical wounds, and can be retained in the body. For surgical wounds, burns, burns and other chronic wounds, covering the wound can prevent moisture loss in body fluids, provide a positive moist environment for wound healing, and keep the wound without effusion, no erosion, and isolate bacterial infection. It can also play a role in reducing inflammation, stopping bleeding and promoting tissue healing.
- the medical dressing prepared by the invention is suitable for the application in the field of surgery and burns, and can be used for preparing surgical wounds, burns and chronic wound dressings.
- the medical dressing prepared by the invention can be made into a wound anti-inflammatory hemostatic cotton and a wound-reducing cotton strip by using the opening treatment, and is used for stopping bleeding in various surgical wounds, and can be absorbed in the body.
- the medical dressing prepared by the invention can also be used as an inner layer dressing of the composite dressing for convenient use.
- a transparent or non-transparent film with a single side with a single side is applied to the outer layer to make an application for surgical wounds.
- the invention has the following beneficial effects:
- the antibacterial medical dressing prepared by the invention is used for surgical wounds, burns, burns and other chronic wounds, covering the wound surface to prevent moisture loss in the body fluid, and providing wound healing A positive moist environment, and keep the wound without effusion, no erosion, isolated bacterial infection, and can play an anti-inflammatory, hemostasis, analgesic, and promote tissue healing.
- the method of the invention solves the disadvantages of the prior art that the carboxymethylated fiber is made into a non-woven fabric by a non-woven process, resulting in hydrophobicity, and also solves the prior art, the carboxymethylated fiber is passed through the non-woven fabric.
- the process is made into a nonwoven fabric, it is difficult to loosen and form a net during the processing of the back nonwoven fabric.
- chitosan fiber was immersed in a 40% NaOH solution at a bath ratio of 1:20, and reacted at room temperature for 0.5 hours to form alkalized chitosan fibers; the alkalized product was washed with absolute alcohol.
- the product is further reacted with chloroacetic acid in isopropanol, the concentration of chloroacetic acid is 20%, the reaction temperature is 35 ° C, the reaction time is 1 hour, the reaction is finished, the excess solution is removed, and the solution is washed with anhydrous ethanol. It is a carboxymethyl chitosan fiber.
- the product is cut, opened, netted, and needled into a 50 g/m 2 non-woven fabric, which can be cut, packaged, and sterilized to form a dressing, called al. Suitable for wounds with a wound surface of less than 10 cm 2 .
- the chitosan fiber was mixed with the carboxymethyl chitosan fiber used for the preparation of al by a mass ratio of 9:1, opened, netted, and needle-punched to make a 100 g/m 2 non-woven fabric, which was cut, packaged, Disinfection can be made into a dressing, called a2. Suitable for burns and burns of larger wounds.
- the nano-silver particles are added in a ratio of 0.1% by mass in the spinning solution, and the chitosan fiber containing the nano-silver particles and the carboxy-based chitosan can be prepared.
- a sugar fiber blended nonwoven medical dressing, the product is called a3.
- Example 4 The sodium carboxymethyl chitosan fibers in a1 are soaked in a silver nitrate solution dissolved in ethanol to exchange sodium ions and silver ions.
- the concentration of the silver nitrate solution is 0.5%
- the reaction temperature is 20 ° C
- the reaction time is 0.5 hours
- the reaction is finished
- the excess solution is removed, washed with anhydrous ethanol, and air-dried is a carboxymethyl chitosan containing silver ions. fiber.
- a nonwoven medical dressing of carboxymethyl chitosan fibers containing silver ions was finally produced, which was called a4.
- chitosan fiber 100 g of chitosan fiber is immersed in a concentration of 45% NaOH solution, and the bath ratio is 1:40, and reacted at room temperature for 1 hour to form alkalized chitosan fiber; the alkalized product is washed with anhydrous alcohol; The product is further reacted with chloroacetic acid in isopropanol, the concentration of chloroacetic acid is 30%, the reaction temperature is 60 ° C, the reaction time is 3 hours, the reaction is completed, the excess solution is removed, washed with absolute ethanol, and air-dried is carboxymethyl Chitosan fiber.
- the product is cut, opened, netted, and needled into a 50 g/m 2 non-woven fabric, which can be cut, packaged, and sterilized to form a dressing, called bl.
- a dressing called bl.
- the chitosan fiber was mixed with the carboxymethyl chitosan fiber used for the preparation of bl by mass ratio of 8 : 2, opened, netted, needled and made into a 100 g / m 2 non-woven fabric, which was cut and packaged. , disinfection can be made into a dressing, b2. Suitable for burns and burns of larger wounds.
- the nano-silver particles are added in a ratio of 0.5% by mass in the spinning solution, and the chitosan fiber and the carboxymethyl shell-containing polymer containing the nano silver particles can be prepared.
- a woven sugar fiber blended nonwoven medical dressing. This product is called b3.
- the carboxymethyl chitosan fibers in bl were soaked in a silver nitrate solution dissolved in ethanol to exchange sodium ions and silver ions.
- the concentration of the silver nitrate solution was 5%
- the reaction temperature was 25 Torr
- the reaction time was 1 hour
- the excess solution was removed, washed with absolute ethanol, and air-dried to be a carboxymethyl chitosan fiber containing silver ions.
- a nonwoven medical dressing of carboxymethyl chitosan fibers containing silver ions is finally produced, which is called b4. .
- Example 9 100 g of chitosan fiber was immersed in a 50% NaOH solution at a bath ratio of 1:60, and reacted at room temperature for 6 hours to form an alkalized chitosan fiber; the alkalized product was anhydrous. Alcohol wash Net; this product is further reacted with chloroacetic acid in isopropanol, the concentration of chloroacetic acid is 40%, the reaction temperature is 75 ° C, the reaction time is 8 hours, the reaction is finished, the excess solution is removed, washed with absolute ethanol, air-dried It is a carboxymethyl chitosan fiber.
- the product is cut, opened, netted, and needled into a 50 g/m 2 non-woven fabric, which can be cut, packaged, and sterilized to form a dressing, which is called clo, suitable for wounds with a wound surface of less than 10 cm 2 .
- the chitosan fiber and the carboxymethyl chitosan fiber used for preparing cl were mixed, opened, netted and needled at a mass ratio of 1:9 to make a 100 g/m 2 non-woven fabric, which was cut and packaged. Disinfection, ie 3 ⁇ 4J, is made into a dressing called c2. . Suitable for burns and burns of larger wounds.
- the nano-silver particles are added in a ratio of 1% by mass in the spinning solution, and the chitosan fiber and the carboxymethyl chitosan fiber containing the nano silver particles can be prepared.
- a blended nonwoven medical dressing, the product is referred to as c3.
- the carboxymethyl chitosan fibers in cl were soaked in a silver nitrate solution dissolved in ethanol to exchange sodium ions and silver ions.
- the concentration of the silver nitrate solution was 10%
- the reaction temperature was 30 ° C
- the reaction time was 2 hours
- the excess solution was removed, washed with absolute ethanol, and air-dried to be a carboxymethyl chitosan fiber containing silver ions.
- a nonwoven fabric medical material, which is finally made into a carboxymethyl chitosan fiber containing silver ions, is called c4.
- the alkalized chitosan nonwoven fabric is formed by immersing 100 g of chitosan non-woven fabric in a 40% NaOH solution at a bath ratio of 1:20 at room temperature for 0.5 hours; Alcohol washing; the product is further reacted with chloroacetic acid in isopropanol, the concentration of chloroacetic acid is 20%, the reaction temperature is 35 ° C, the reaction time is 1 hour, the reaction is finished, the excess solution is removed, and the solution is washed with anhydrous ethanol.
- Air-drying is a carboxymethyl chitosan non-woven fabric, which can be made into a dressing after cutting, packaging and disinfection. The product is called dl. Suitable for wounds with a wound surface of less than 10 cm 2 .
- the carboxymethyl chitosan nonwoven fabric from which dl was prepared was immersed in a silver nitrate solution dissolved in ethanol to exchange sodium ions and silver ions. 5 % ⁇ The concentration of the silver nitrate solution is 0.5%, the reaction temperature 20 ° C, reaction time 0.5 hours, the reaction is completed, the excess solution is removed, washed with anhydrous ethanol, air-dried is a carboxymethyl chitosan nonwoven fabric containing silver ions, 'this product is called d2.
- chitosan non-woven fabric 100 g was immersed in a 45% NaOH solution at a bath ratio of 1:40, and reacted at room temperature for 1 hour to form an alkalized chitosan nonwoven fabric; the alkalized product was washed with anhydrous alcohol. Net; this product is further reacted with chloroacetic acid in isopropanol, the concentration of chloroacetic acid is 30%, the reaction temperature is 60 ° C, the reaction time is 3 hours, the reaction is finished, the excess solution is removed, washed with absolute ethanol, air-dried
- the carboxymethyl chitosan non-woven fabric can be made into a dressing by cutting, packaging and disinfecting, and the product is called el. Suitable for wounds with a wound surface of less than 10 cm 2 .
- the carboxymethyl chitosan nonwoven fabric from which el was prepared was immersed in a silver nitrate solution dissolved in ethanol to exchange sodium ions and silver ions.
- the concentration of the silver nitrate solution is 5%
- the reaction temperature is 25 ° C
- the reaction time is 1 hour
- the reaction is completed
- the excess solution is removed, washed with anhydrous ethanol, and air-dried is a carboxymethyl chitosan nonwoven fabric containing silver ions.
- This product is called e2.
- chitosan non-woven fabric 100 g was immersed in a concentration of 50.% NaOH solution, and the bath ratio was 1:60, and reacted at room temperature for 6 hours to form an alkalized chitosan nonwoven fabric; the alkalized product was anhydrous alcohol. Washing; the product is further reacted with chloroacetic acid in isopropanol, the concentration of chloroacetic acid is 40%, the reaction temperature is 75 ° C, the reaction time is 8 hours, the reaction is finished, the excess solution is removed, washed with absolute ethanol, air-dried That is, the carboxymethyl chitosan non-woven fabric can be made into a dressing by cutting, packaging and disinfecting, and the product is called cockroach. Suitable for wounds with a wound less than lOcrn 2 .
- the carboxymethyl chitosan nonwoven fabric from which fl was prepared was immersed in a silver nitrate solution dissolved in ethanol to exchange sodium ions and silver ions.
- the concentration of the silver nitrate solution is 10%
- the reaction temperature is 30 V
- the reaction time is 2 hours
- the reaction is completed
- the excess solution is removed
- the solution is washed with absolute ethanol, and air-dried is a carboxymethyl chitosan nonwoven fabric containing silver ions.
- This product is called f2.
- the dressing a is juxtaposed in a plasma reaction device to which a capacitive coupling is connected.
- the dressing is subjected to hydrophilic grafting or polymerization, and its working condition is that oxygen is supplied to the reactor under vacuum, and the graft polymerization is carried out after modification, and the background vacuum is 2 Pa, glow discharge.
- Modified pressure is 20 Pa, modification time is 1 minute; graft polymerization pressure is 10 Pa, time is 2 minutes, and discharge power is 30 W.
- the resulting product is called Al.
- the dressings al are placed side by side in a plasma reaction device to which capacitive coupling is applied.
- the dressing is subjected to hydrophilic grafting or polymerization.
- the working conditions are nitrogen (or hydrogen) to the reactor under vacuum, and the graft polymerization is carried out after modification, and the background vacuum is 6 Pa, glow discharge.
- the modified pressure is 40 Pa and the modification time is 15 minutes; the graft polymerization pressure is 30 Pa, the time is 20 minutes, and the discharge power is 50 W.
- the resulting product is called Bl.
- the dressings al are placed side by side in a plasma reaction device to which capacitive coupling is applied.
- the dressing is subjected to hydrophilic grafting or polymerization.
- the working conditions are that an inert gas is introduced into the reactor under vacuum, and the graft polymerization is carried out after modification, and the background vacuum is 8 Pa, glow discharge.
- the modified pressure is 80 Pa, and the modification time is 30 minutes; the graft polymerization pressure is 60 Pa, the time is 60 minutes, and the discharge power is 80 W.
- the resulting product is called Cl.
- Example 22 'The dressing a was placed in a vacuum oven for thermal crosslinking, and vacuum was applied at 50 Torr for 1 hour; the temperature of the vacuum drying oven was raised to 80 ° C, and the heat treatment time was 2 hours; while maintaining the vacuum state After the temperature in the vacuum oven is lowered to room temperature, the material is taken out, and the treated dressing is sterilized to obtain the product A2, which is stored for use.
- the dressing a1 was placed in a vacuum oven for thermal crosslinking, and vacuum was applied at 60 ° C for 3 hours; the temperature of the vacuum drying crucible was raised to 120 ° C, and the heat treatment treatment time was 1 day; the vacuum treatment was lowered. After the temperature in the vacuum oven reaches room temperature, the material is taken out, and the treated dressing is sterilized to obtain product B2, which is stored for use.
- the dressing a1 was placed in a vacuum oven for thermal crosslinking, and vacuum was applied at 80 ° C for 5 hours; the temperature of the vacuum drying oven was raised to 140 ° C, and the heat treatment treatment time was 4 days; the temperature was lowered while maintaining the vacuum. After the temperature in the vacuum oven reaches room temperature, the material is taken out, and the treated dressing is sterilized to obtain product C2, which is stored for use.
- Example 25 Dip the dressing a into the glutaraldehyde solution, soak for 5 minutes at room temperature; adjust the solution to acidity with acid, and crosslink at room temperature for 2 hours; repeatedly rinse the medical dressing with phosphate buffer solution until the uncrosslinked crosslinker is removed.
- the treated dressing is sterilized to obtain product A3, which is stored for use.
- the dressing al is placed under an ultraviolet lamp having a wavelength of 253.7 nm; the medical dressing is irradiated with ultraviolet light for 30 minutes, ultraviolet cross-linking is performed, and the treated dressing is sterilized to obtain a product B4, which is stored for use.
- the nonwoven fabric dressings prepared in Examples 1 to 10 were cut into 10 cm x 10 cm, and surgical wounds, burns, and chronic wound dressings were prepared by packaging and disinfecting.
- Example 32 The non-woven fabric dressings prepared according to Examples 1 to 10 were cut into 4 cm X 20 cm, and then attached to a rubberized surface of a 9 C mX 25 cm transparent film having a medical adhesive on one side, and a silicone paper was attached to the rubberized surface. , surgical packaging can be obtained by packaging and disinfection.
- Examples packaged nonwoven fabric 110 will be made to the embodiment, can be prepared disinfection antiphlogistic hemostatic wound tampon 0
- the non-woven fabric dressings prepared according to Examples 1 to 10. were cut into 4 cm x 20 cm, and the wound anti-inflammatory draining sliver was prepared by packaging and disinfecting.
- test samples were made according to Examples 1 to 18; the control samples were ordinary medical gauze (Shanghai Knitting 21 Factory).
- the inspection technology is based on the evaluation of antibacterial properties of fabrics after AATCC100-1999. Table 1, antibacterial test results
- Carboxymethyl chitosan nonwoven fabric a (test sample) prepared according to Example 1, according to Example 19-21, product after low temperature plasma treatment, Al, Bl, CI (test sample) , Ordinary medical double gauze (control sample, Shanghai Knitting II H" "- factory", are cut into 5cmX 5cm.
- test solution 8. 298 g of sodium chloride and 0.368 g of calcium chloride dissolved in 1000 ml of deionized water.
- Analytical balance (accuracy O. OOlg); incubator; leather petri dish.
- Liquid absorbency is calculated according to the following formula:
- sample According to Examples 22 to 30, antibacterial medical dressings (test samples) subjected to various cross-linking treatments, uncrosslinked antibacterial medical dressings prepared according to Example 1 (control sample) , all cut into 2cmX4cm ;
- the sample is placed in a deionized water solution, the amount added is 40 times the mass of the sample;
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Materials Engineering (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Textile Engineering (AREA)
- Materials For Medical Uses (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
- Nonwoven Fabrics (AREA)
- Chemical Or Physical Treatment Of Fibers (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/886,459 US20080241229A1 (en) | 2005-03-17 | 2005-12-22 | Preparation Method of an Anti-Microbial Wound Dressing and the Use Thereof |
DE602005023353T DE602005023353D1 (de) | 2005-03-17 | 2005-12-22 | Verfahren zur herstellung und verwendung eines antiseptischen medizinischen verbands |
AT05822619T ATE479452T1 (de) | 2005-03-17 | 2005-12-22 | Verfahren zur herstellung und verwendung eines antiseptischen medizinischen verbands |
PL05822619T PL1859816T3 (pl) | 2005-03-17 | 2005-12-22 | Sposób wytwarzania i zastosowanie antyseptycznego opatrunku medycznego |
JP2008501137A JP5075811B2 (ja) | 2005-03-17 | 2005-12-22 | 抗菌創傷包帯の作製方法およびその使用 |
EP05822619A EP1859816B1 (en) | 2005-03-17 | 2005-12-22 | The preparing method and the use of antiseptic medical dressing |
AU2005329351A AU2005329351B2 (en) | 2005-03-17 | 2005-12-22 | The preparing method and the use of antiseptic medical dressing. |
CN2005800491233A CN101141985B (zh) | 2005-03-17 | 2005-12-22 | 抗菌医用敷料的制造方法及其用途 |
HK08105047.4A HK1115072A1 (en) | 2005-03-17 | 2008-05-06 | The preparing method and the use of antiseptic medical dressing |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200510024442.0 | 2005-03-17 | ||
CN200510024442 | 2005-03-17 | ||
CN200510088100.5 | 2005-08-03 | ||
CNA2005100881005A CN1833732A (zh) | 2005-03-17 | 2005-08-03 | 一种抗菌医用敷料的制造方法及其用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006097024A1 true WO2006097024A1 (fr) | 2006-09-21 |
Family
ID=36991270
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2005/002290 WO2006097024A1 (fr) | 2005-03-17 | 2005-12-22 | Procede de preparation et utilisation de pansement medical antiseptique |
Country Status (10)
Country | Link |
---|---|
US (1) | US20080241229A1 (zh) |
EP (1) | EP1859816B1 (zh) |
JP (1) | JP5075811B2 (zh) |
CN (1) | CN1833732A (zh) |
AT (1) | ATE479452T1 (zh) |
AU (1) | AU2005329351B2 (zh) |
DE (1) | DE602005023353D1 (zh) |
HK (1) | HK1115072A1 (zh) |
PL (1) | PL1859816T3 (zh) |
WO (1) | WO2006097024A1 (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2156849A1 (en) * | 2007-05-13 | 2010-02-24 | Qingdao Biotemed Biomaterial Co., Ltd | A chitosan based fiber material, preparing method and application thereof |
JP2011507562A (ja) * | 2007-12-06 | 2011-03-10 | ナノシス・インク. | 吸収性ナノ強化止血構造体及び包帯材料 |
JP2011518592A (ja) * | 2008-04-25 | 2011-06-30 | メッドトレイド プロダクツ リミテッド | 止血材 |
CN110959676A (zh) * | 2018-09-30 | 2020-04-07 | 内蒙古伊利实业集团股份有限公司 | 一种含乳双歧杆菌的发酵乳制品及其应用 |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060004314A1 (en) * | 2001-06-14 | 2006-01-05 | Hemcon, Inc. | Antimicrobial barriers, systems, and methods formed from hydrophilic polymer structures such as chistosan |
US8741335B2 (en) | 2002-06-14 | 2014-06-03 | Hemcon Medical Technologies, Inc. | Hemostatic compositions, assemblies, systems, and methods employing particulate hemostatic agents formed from hydrophilic polymer foam such as Chitosan |
US7371403B2 (en) * | 2002-06-14 | 2008-05-13 | Providence Health System-Oregon | Wound dressing and method for controlling severe, life-threatening bleeding |
DK1401352T3 (da) | 2001-06-14 | 2012-06-25 | Kenton W Gregory | Fremgangsmåde til fremstilling af en chitosansårforbinding |
US20050137512A1 (en) | 2003-12-23 | 2005-06-23 | Campbell Todd D. | Wound dressing and method for controlling severe, life-threatening bleeding |
US8269058B2 (en) * | 2002-06-14 | 2012-09-18 | Hemcon Medical Technologies, Inc. | Absorbable tissue dressing assemblies, systems, and methods formed from hydrophilic polymer sponge structures such as chitosan |
US20090130186A1 (en) * | 2002-06-14 | 2009-05-21 | Hemcon Medical Technologies, Inc. | Wound dressing assemblies, systems, and methods formed from hydrophilic polymer sponge structures such as chitosan and incorporating silver nanoparticles |
US9204957B2 (en) | 2005-03-17 | 2015-12-08 | Hemcon Medical Technologies, Inc. | Systems and methods for hemorrhage control and or tissue repair |
WO2007139845A2 (en) | 2006-05-23 | 2007-12-06 | Providence Health System-Oregon D/B/A Providence St. Vincent Medical Center | Systems and methods for introducing and applying a bandage structure within a body lumen or hollow body organ |
US8932560B2 (en) | 2007-09-04 | 2015-01-13 | University of Maryland, College Parke | Advanced functional biocompatible polymeric matrix used as a hemostatic agent and system for damaged tissues and cells |
CN101036799B (zh) * | 2007-04-27 | 2010-05-19 | 东华大学 | 一种可吸收抗菌止血敷料的制备方法 |
GB0719065D0 (en) * | 2007-09-29 | 2007-11-07 | Smith & Nephew | coalescing materials |
WO2009134447A1 (en) | 2008-05-02 | 2009-11-05 | Providence Health System-Oregon D/B/A Providence St. Vincent Medical Center | Wound dressing devices and methods |
US20110274726A1 (en) | 2008-10-06 | 2011-11-10 | Providence Health System - Oregon | Chitosan foam medical devices and methods |
EP2498820B1 (en) | 2009-11-13 | 2019-01-09 | University of Maryland, College Park | Advanced functional biocompatible foam used as a hemostatic agent for compressible and non-compressible acute wounds |
EP2504039A4 (en) | 2009-11-25 | 2014-07-02 | Univ Loma Linda Med | HEMOSTATIC TEXTILE BASED ON CHITOSAN |
GB0922664D0 (en) | 2009-12-24 | 2010-02-10 | Adv Med Solutions Ltd | Chitosan based antimicrobial absorbent material |
CN102134809B (zh) * | 2010-01-25 | 2013-01-02 | 安徽甲特生物科技有限公司 | 一种壳聚糖抗菌功能纱布及制造方法 |
CN102028966B (zh) * | 2010-12-29 | 2013-04-17 | 苏州方策科技发展有限公司 | 一种具有高度吸水溶胀性能的壳聚糖止血膜的制作方法 |
GB201100425D0 (en) * | 2011-01-11 | 2011-02-23 | Lantor Uk Ltd | Process & dressing |
CN102108637B (zh) * | 2011-01-19 | 2012-06-27 | 刘建鸿 | 可溶化止血棉的制作方法 |
CN102727925B (zh) * | 2011-04-02 | 2014-09-17 | 佛山市优特医疗科技有限公司 | 酰化壳聚糖伤口敷料、其制备方法及其应用 |
GB201205174D0 (en) | 2012-03-23 | 2012-05-09 | Medtrade Products Ltd | Process for producing low endotoxin chitosan |
US20210052767A1 (en) * | 2012-04-23 | 2021-02-25 | Foshan United Medical Technologies Ltd. | Antimicrobial fiber comprising silver, fabric and wound dressing comprising the antimicrobial fiber, and methods for manufacturing the fiber, the fabric, and the wound dressing |
CN103170004B (zh) * | 2012-04-23 | 2016-08-31 | 佛山市优特医疗科技有限公司 | 一种制备含银纤维伤口敷料的方法 |
US8899277B2 (en) * | 2012-08-03 | 2014-12-02 | Shin Era Technology Co., Ltd. | Manufacturing method of medical textiles woven from chitosan containing high wet modulus rayon fibre |
GB2511528A (en) | 2013-03-06 | 2014-09-10 | Speciality Fibres And Materials Ltd | Absorbent materials |
CA2914610C (en) | 2013-03-13 | 2022-08-02 | University Of Maryland | Advanced functional biocompatible polymer putty used as a hemostatic agent for treating damaged tissue and cells |
GB201309606D0 (en) * | 2013-05-29 | 2013-07-10 | Medtrade Products Ltd | Process for producing low endotoxin chitosan |
GB201309607D0 (en) * | 2013-05-29 | 2013-07-10 | Medtrade Products Ltd | Process for producing low endotoxin chitosan |
GB2514592A (en) | 2013-05-30 | 2014-12-03 | Medtrade Products Ltd | Degradable haemostat composition |
KR101311990B1 (ko) * | 2013-07-18 | 2013-09-27 | 오스템임플란트 주식회사 | 임플란트 표면의 생체활성과 골결합력 및 골융합을 증진시키는 물질이 코팅된 임플란트와 그 제조방법 및 임플란트의 보관 방법 |
CN103961738B (zh) * | 2014-04-11 | 2015-12-09 | 武汉工程大学 | 一种壳聚糖-纳米银伤口敷料及其制备方法 |
US9259357B2 (en) | 2014-04-16 | 2016-02-16 | Loma Linda University | Composition, preparation, and use of chitosan shards for biomedical applications |
CN104358123B (zh) * | 2014-11-19 | 2016-08-24 | 武汉理工大学 | 一种丙酰氧基乙基三甲基氯化铵壳聚糖纤维的制备方法 |
CN106267300B (zh) * | 2015-05-14 | 2020-09-15 | 北京化工大学 | 一种兼具杀菌止血性和生化战剂防护性的多功能材料及其制备方法 |
CN104958779B (zh) * | 2015-06-25 | 2018-03-20 | 佛山市优特医疗科技有限公司 | 一种含有螯合银纤维的伤口敷料 |
CN105671942A (zh) * | 2016-01-07 | 2016-06-15 | 江苏天章医用卫生新材料有限公司 | 医用抗菌棉纱布的制备方法 |
CN107177980B (zh) * | 2016-03-12 | 2020-09-01 | 山东美泰医药有限公司 | 一种接触性创面敷料及其制备方法 |
WO2018075456A1 (en) * | 2016-10-17 | 2018-04-26 | Gel-E Life Sciences | Materials comprising hydrophobically-modified biopolymer |
CN106731225B (zh) * | 2016-12-07 | 2018-12-14 | 盐城工学院 | 一种抗菌滤料及其整理方法 |
WO2019066131A1 (ko) * | 2017-09-29 | 2019-04-04 | 주식회사 엔도비전 | 자궁 경부용 키토산 기반의 지혈부재 및 이의 제조방법 |
CN108385276A (zh) * | 2018-01-22 | 2018-08-10 | 潍坊爱普长实化工有限公司 | 一种低克重吸水无纺布及其生产工艺和应用 |
CN109077851B (zh) * | 2018-09-05 | 2021-09-03 | 安信纳米生物科技(珠海)有限公司 | 一种高吸液纳米银抗菌保湿医用敷料及其制备方法 |
CN113106623B (zh) * | 2021-04-07 | 2022-04-08 | 深圳市一秋医纺科技有限公司 | 一种防感染复合层医用敷料、床单及用途 |
CN113616849B (zh) * | 2021-08-16 | 2022-11-22 | 牡丹江医学院 | 一种用于外部伤口护理的液体敷料及其制备方法 |
CN113830879B (zh) * | 2021-09-02 | 2024-03-19 | 中工武大设计集团有限公司 | 一种壳聚糖表面涂覆改性绳状人工水草及其制备方法 |
CN113699788B (zh) * | 2021-09-06 | 2023-06-16 | 江阴市宏勇医疗科技发展有限公司 | 一种抗静电抗酒精抗血浆医用无纺布 |
CN115006580B (zh) * | 2022-01-24 | 2023-05-30 | 东华大学 | 一种可编织纳米纤维纱线和水凝胶复合敷料及其制备方法 |
CN115625940A (zh) * | 2022-09-07 | 2023-01-20 | 浙江大学医学院附属第一医院 | 蚕丝复合无纺布敷料及其制备方法和用途 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1298972A (zh) * | 1999-12-09 | 2001-06-13 | 海南欣龙无纺股份有限公司 | 甲壳质纤维水刺无纺布及其生产方法 |
CN1431229A (zh) * | 2003-01-09 | 2003-07-23 | 武汉大学 | 羧甲基壳聚糖及其制备方法和用途 |
CN1493364A (zh) * | 2002-10-30 | 2004-05-05 | 郑婵颖 | 壳聚糖生物敷料的制造方法 |
US20050058694A1 (en) | 1999-10-07 | 2005-03-17 | Coloplast A/S | Wound care device |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4619995A (en) * | 1984-12-24 | 1986-10-28 | Nova Chem Limited | N,O-carboxymethyl chitosan and preparative method therefor |
JPS61240963A (ja) * | 1985-04-18 | 1986-10-27 | ユニチカ株式会社 | 創傷被覆保護材 |
US4946870A (en) * | 1986-06-06 | 1990-08-07 | Union Carbide Chemicals And Plastics Company Inc. | Delivery systems for pharmaceutical or therapeutic actives |
JPH0676441B2 (ja) * | 1989-12-12 | 1994-09-28 | 第一工業製薬株式会社 | キトサンのカルボキシメチルエーテル塩の製造方法 |
JP3046099B2 (ja) * | 1991-06-19 | 2000-05-29 | ユニチカ株式会社 | キチン又はキトサンの綿状物 |
JP2996773B2 (ja) * | 1991-06-19 | 2000-01-11 | ユニチカ株式会社 | キチン不織布の製造方法 |
GB9126193D0 (en) * | 1991-12-10 | 1992-02-12 | Courtaulds Plc | Cellulosic fibres |
GB9400994D0 (en) * | 1994-01-20 | 1994-03-16 | Bristol Myers Squibb Co | Wound dressing |
US5621088A (en) * | 1995-04-10 | 1997-04-15 | Amerchol Corporation | Process for derivatizing polyglucosamines |
US20020147318A1 (en) * | 2001-04-09 | 2002-10-10 | Cho Fu Chuan | Preparation method of water soluble carboxylmethyl chitosan having anti-lipid peroxidation ability |
US6627750B2 (en) * | 2001-08-03 | 2003-09-30 | Rayonier Inc. | Highly carboxylated cellulose fibers and process of making the same |
JP4192467B2 (ja) * | 2001-12-17 | 2008-12-10 | 凸版印刷株式会社 | 酸化多糖類材料の製造方法及び酸化多糖類材料 |
-
2005
- 2005-08-03 CN CNA2005100881005A patent/CN1833732A/zh active Pending
- 2005-12-22 US US11/886,459 patent/US20080241229A1/en not_active Abandoned
- 2005-12-22 EP EP05822619A patent/EP1859816B1/en not_active Not-in-force
- 2005-12-22 WO PCT/CN2005/002290 patent/WO2006097024A1/zh active Application Filing
- 2005-12-22 AT AT05822619T patent/ATE479452T1/de not_active IP Right Cessation
- 2005-12-22 JP JP2008501137A patent/JP5075811B2/ja not_active Expired - Fee Related
- 2005-12-22 AU AU2005329351A patent/AU2005329351B2/en not_active Ceased
- 2005-12-22 PL PL05822619T patent/PL1859816T3/pl unknown
- 2005-12-22 DE DE602005023353T patent/DE602005023353D1/de active Active
-
2008
- 2008-05-06 HK HK08105047.4A patent/HK1115072A1/xx not_active IP Right Cessation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050058694A1 (en) | 1999-10-07 | 2005-03-17 | Coloplast A/S | Wound care device |
CN1298972A (zh) * | 1999-12-09 | 2001-06-13 | 海南欣龙无纺股份有限公司 | 甲壳质纤维水刺无纺布及其生产方法 |
CN1493364A (zh) * | 2002-10-30 | 2004-05-05 | 郑婵颖 | 壳聚糖生物敷料的制造方法 |
CN1431229A (zh) * | 2003-01-09 | 2003-07-23 | 武汉大学 | 羧甲基壳聚糖及其制备方法和用途 |
Non-Patent Citations (1)
Title |
---|
L CHEN ET AL.: "Studies on Carboxymethyl Chitosan's Structure and Anti-microbial Capabilities", JOURNAL OF WUHAN UNIVERSITY, April 2000 (2000-04-01) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2156849A1 (en) * | 2007-05-13 | 2010-02-24 | Qingdao Biotemed Biomaterial Co., Ltd | A chitosan based fiber material, preparing method and application thereof |
EP2156849B1 (en) * | 2007-05-13 | 2017-10-25 | Qingdao Biotemed Biomaterial Co., Ltd | A chitosan based fiber material, preparing method and application thereof |
JP2011507562A (ja) * | 2007-12-06 | 2011-03-10 | ナノシス・インク. | 吸収性ナノ強化止血構造体及び包帯材料 |
JP2011518592A (ja) * | 2008-04-25 | 2011-06-30 | メッドトレイド プロダクツ リミテッド | 止血材 |
JP2015128600A (ja) * | 2008-04-25 | 2015-07-16 | メッドトレイド プロダクツ リミテッドMedtrade Products Limited | 止血材 |
JP2015128601A (ja) * | 2008-04-25 | 2015-07-16 | メッドトレイド プロダクツ リミテッドMedtrade Products Limited | 止血材 |
CN110959676A (zh) * | 2018-09-30 | 2020-04-07 | 内蒙古伊利实业集团股份有限公司 | 一种含乳双歧杆菌的发酵乳制品及其应用 |
Also Published As
Publication number | Publication date |
---|---|
PL1859816T3 (pl) | 2011-04-29 |
CN1833732A (zh) | 2006-09-20 |
DE602005023353D1 (de) | 2010-10-14 |
EP1859816B1 (en) | 2010-09-01 |
JP5075811B2 (ja) | 2012-11-21 |
EP1859816A1 (en) | 2007-11-28 |
JP2008532662A (ja) | 2008-08-21 |
AU2005329351B2 (en) | 2011-12-01 |
HK1115072A1 (en) | 2008-11-21 |
EP1859816A4 (en) | 2008-11-05 |
US20080241229A1 (en) | 2008-10-02 |
ATE479452T1 (de) | 2010-09-15 |
AU2005329351A1 (en) | 2006-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006097024A1 (fr) | Procede de preparation et utilisation de pansement medical antiseptique | |
JP2617260B2 (ja) | 創傷治療用ゲル配合物 | |
JP6974177B2 (ja) | 創傷被覆材用の組成物 | |
JP6768705B2 (ja) | 創傷被覆材用の組成物 | |
JP6974176B2 (ja) | 創傷被覆材用の組成物 | |
US20070104769A1 (en) | Bioabsorbable hemostatic gauze | |
CN104623718B (zh) | 壳聚糖凡士林纱布及其制备方法 | |
CN108785732B (zh) | 止血封堵材料及其制备方法和止血封堵制品 | |
Singh et al. | Application of tragacanth gum and alginate in hydrogel wound dressing's formation using gamma radiation | |
WO2007056066A2 (en) | Bioabsorbable hemostatic gauze | |
CN101141985A (zh) | 抗菌医用敷料的制造方法及其用途 | |
US20210322225A1 (en) | Lint Free Crosslinked Chitosan-PVA Sponge as an Absorbent Wound Dressing and Method of Preparation Thereof | |
US9681992B2 (en) | Wound care device | |
CN106947095A (zh) | 一种用于伤口愈合抑菌型水凝胶的制备方法 | |
RU2275179C2 (ru) | Повязка для закрытия и лечения ожогов | |
KR100372560B1 (ko) | 숯 충진 수화겔 드레싱 및 방사선을 이용한 그의 제조방법 | |
RU37463U1 (ru) | Покрытие для ожоговых ран | |
CN114452433B (zh) | 医用敷料、制备方法、应用及创口敷料贴 | |
WO2012075658A1 (zh) | 一种医用敷料的制备方法 | |
UA28513U (uk) | Антисептичний перев`язувальний матеріал |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 200580049123.3 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008501137 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005822619 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005329351 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: 2005329351 Country of ref document: AU Date of ref document: 20051222 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005329351 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2005822619 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11886459 Country of ref document: US |